Acorda, Hayman Capital Management autoimmune news
The U.S. Patent and Trademark Office denied two inter partes review (IPR) petitions filed in February by hedge fund manager Kyle Bass challenging two patents for Acorda’s Ampyra dalfampridine for multiple sclerosis (MS). The petitions challenged Patent No. 8,633,685, which expires in 2025, and Patent No. 8,007,826, which expires in 2027. The PTO’s Patent Trials and Appeals Board (PTAB) said the petitions presented insufficient evidence against the patents. The petitions referenced poster presentations to support the arguments that Acorda’s claims were available in the prior art. PTAB concluded that the posters do not qualify as printed publications and thus do not constitute prior art. Ampyra is a sustained-release formulation of 4-aminopyridine (4-AP) (see BioCentury, June 1). ...